生物法制备细菌多糖结合疫苗的研究进展  

Recent Advances in Preparation of Bacterial Polysaccharide Conjugate Vaccines by Biosynthetic Method

作　　者：潘超 朱力 王恒樑 Pan Chao;Zhu Li;Wang Hengliang(Beijing Institute of Biotechnology,Beijing100071)

机构地区：[1]军事科学院军事医学研究院生物工程研究所,北京100071

出　　处：《中国科学基金》2020年第5期594-601,共8页Bulletin of National Natural Science Foundation of China

基　　金：国家自然科学基金重点项目(81930122);面上项目(81871314)的资助。

摘　　要：多糖结合疫苗被认为是目前最为成功的细菌性疫苗形式之一,在人类传染病防控方面发挥了巨大作用。然而,目前多糖结合疫苗的制备所采用的化学偶联方法生产成本高、产品均一性低、环保压力大,制约着这种疫苗的进一步发展。近年来逐渐兴起的生物法制备策略主要利用细菌中蛋白糖基化系统,采用全生物合成的方法只需一步即可高效制备多糖结合疫苗,很好地解决了化学法的不足,并且使新一代疫苗具备了更大的定向设计空间和发展潜力。本文梳理了生物法制备多糖结合疫苗的研究成果及最新进展,明确了生物制备方法中的关键环节,并对多糖结合疫苗的进一步优化提出了建议。The polysaccharide conjugate vaccine is considered to be one of the most successful bacterial vaccines at present,and has played a huge role in preventing infectious diseases in humans.However,the chemical method for preparing polysaccharide conjugate vaccines is a multi-step,complex process,which has the disadvantages of high cost,low product uniformity and environmental pollution.In recent years,emerging biosynthetic method strategies are expected to solve the deficiencies of chemical ones.This method only needs one step to produce polysaccharide conjugate in vivo using protein glycosylation system and could provide more choices for the rational design of further development.This article reviews the latest progress in the preparation of polysaccharide conjugate vaccines by biosynthetic method,and puts forward the key points of this method,which provides directions for the design and optimization of polysaccharide conjugate vaccines in the future.

关 键 词：多糖结合疫苗 生物合成 蛋白糖基化 病原细菌 

分 类 号：R392-33[医药卫生—免疫学]